Forget Nvidia and SpaceX - These 5 Stocks Could Soar Next
Everyone is watching SpaceX.
But Wall Street’s top-rated analysts are pointing to 5 different stocks right now.
MarketBeat’s Top 5 Stocks to Buy Now report reveals the names getting some of the strongest analyst support before the broader market catches on.
A constructive tape raises the proof standard
Good morning. Broad market participation is supporting risk appetite, but in medical devices the next results will separate software-led margin gains from growth stories that still need to prove their earnings path. Today’s market read Markets look constructive, with broad participation and stronger leadership. 01. Market Direction: Positive. Major indexes are trending higher across more time frames. 02. Market Participation: Broadening. More stocks are joining in. 03. Strongest Sector: Technology. Investors are showing the most interest here right now.
Today’s market read
Markets look constructive, with broad participation and stronger leadership.
01 Market Direction
Positive. Major indexes are trending higher across more time frames.
02 Market Participation
Broadening. More stocks are joining in.
03 Strongest Sector
Technology. Investors are showing the most interest here right now.
Medical devices split at the margin
Key points
Butterfly Network delivered $32.6 million in second-quarter revenue, beat consensus, and raised its 2026 outlook.
Its software and licensing mix helped lift gross margin to 71.4%, while net losses and cash use remain material.
Haemonetics and Establishment Labs report August 6, putting renewed growth, U.S. demand, and profitability paths under focus.
The medical-device group has moved higher with unusually broad participation, but that strength does not create one shared operating story. The relevant question is whether each company can turn demand into durable revenue quality, margin progress, and guidance that supports the next stage of expectations.
Butterfly Network offers the clearest recent example. In this medical-device earnings setup, second-quarter sales reached $32.6 million, up 39% year over year and above the $29.2 million consensus estimate. Gross margin rose to 71.4% from 63.7% as software and licensing contributed more to the mix, and management lifted its 2026 revenue outlook to $119 million to $123 million.
That evidence is constructive, but it is not a finished profitability case. Butterfly still carries a material net loss and cash use, so investors will need to see whether the richer mix can persist while spending stays disciplined. The next reports offer different tests. Haemonetics needs its existing profitability to be matched by renewed revenue and earnings growth, while Establishment Labs needs U.S. Motiva demand to support guidance and narrow the route toward net profitability.
With the industry already up sharply over the past one and three months, the August 6 reports matter less as a verdict on healthcare sentiment and more as a check on execution. Revenue conversion, gross-margin direction, and forward guidance are the evidence that can distinguish a broad group advance from company-specific progress.
The market backdrop is constructive, but the useful watch item is whether upcoming reports confirm that participation is being matched by operating leverage, rather than simply by a higher tolerance for growth narratives.